Native NAD-dependent GAPDH replaced with NADP-dependent GAPDH plus NADK
US8709753B2 · kind B2 · utility
3Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 19, 2012 |
| Grant date | Apr 29, 2014 |
| Priority date | — |
| Expiry date | Nov 19, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y207/01023
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention is metabolically engineer bacterial strains that provide increased intracellular NADPH availability for the purpose of increasing the yield and productivity of NADPH-dependent compounds. In the invention, native NAD-dependent GAPDH is replaced with NADP-dependent GAPDH plus overexpressed NADK. Uses for the bacteria are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.